🔬 Third-party verified peptides · Free Express Post over $200 CAD
Pantheon Peptides
Thymosin-Alpha-1 Peptides 2mg
All Peptides

Thymosin Alpha-1

Be the first to review
8 cited studies ↓
$45.00
In stock · Ships within 24hrsSKU: THYMOSIN-ALPHA-1-2MG
Concentration:2mg

Key Health Benefits:

  • Enhances immune function
  • Reduces chronic inflammation
  • Aids in recovery from illness
  • Increase infection resistance
  • Stimulates T-cell production
  • Improves outcomes in chronic conditions

Need supplies?

Get all the reconstitution & injection supplies.

  • Bacteriostatic Water
    Bacteriostatic Water
    $12.50
  • Injection Syringes
    Injection Syringes
    $16.50
  • Alcohol Pads
    Alcohol Pads
    $8.90

About Thymosin Alpha-1

Thymosin Alpha-1 is a powerful peptide recognized for its immune-boosting properties, particularly through its stimulation of T-cells, which are crucial in fighting infections and disease. By modulating immune response, Thymosin Alpha-1 helps reduce chronic inflammation, making it beneficial for managing autoimmune and inflammatory conditions. It enhances the body's defenses against viral, bacterial, and fungal infections, increasing overall resilience. Additionally, Thymosin Alpha-1 supports recovery from illness, strengthens immune function, and may contribute to improved outcomes in chronic conditions. Its comprehensive immune support makes it a valuable option for those seeking enhanced protection and faster recovery from health challenges.

Peer-reviewed studies on Thymosin Alpha-1

Full reference →
  1. (1996). A randomized controlled trial of thymosin-alpha1 versus interferon alfa treatment in patients with hepatitis B e antigen antibody-and hepatitis B virus DNA-positive chronic hepatitis B. Hepatology.
    Read source ↗
  2. (1999). Thymosin alpha1 treatment of chronic hepatitis B: results of a phase III multicentre, randomized, double-blind and placebo-controlled study. Journal of Viral Hepatitis.
    Read source ↗
  3. (2013). The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial. Critical Care.
    Read source ↗
  4. Liu F, Wang HM, Wang T, Zhang YM, Zhu X (2015). The efficacy of thymosin α1 as immunomodulatory treatment for sepsis: a systematic review of randomized controlled trials. BMC Infectious Diseases.
    PMID 26715538Read source ↗
  5. Costantini C, Bellet MM, Pariano M, et al. (2019). A reappraisal of thymosin Alpha1 in cancer therapy. Frontiers in Oncology.
    PMID 31799197Read source ↗
  6. (2022). A Double-blind Multicenter Two-arm Randomized Placebo-controlled Phase-III Clinical Study to Evaluate the Effectiveness and Safety of Thymosin α1 as an Add-on Treatment to Existing Standard of Care Treatment in Moderate-to-severe COVID-19 Patients. Indian Journal of Critical Care Medicine.
    Read source ↗
  7. (2025). The efficacy and safety of thymosin α1 for sepsis (TESTS): multicentre, double-blinded, randomised, placebo-controlled, phase 3 trial. BMJ.
    Read source ↗
  8. (2025). Efficacy of thymosin α1 for sepsis: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Cellular and Infection Microbiology.
    Read source ↗

Reviews

Loading reviews…

Related Products

Peptides are research compounds and are not approved for human use unless prescribed by a licensed medical practitioner.